Stocks
Prime Medicine, Inc.PRME
NASDAQHealthcareBiotechnology$3.67
Price as of · delayed, not real-time
A clinical-stage biotechnology company developing a proprietary gene editing platform based on prime editing technology. The company's programs target genetic diseases in the liver, eye, and hematopoietic stem cells, with a focus on creating durable corrections rather than gene disruption. Investors track PRME for its potential to expand the therapeutic reach of gene editing beyond existing nuclease-based approaches.
52W Range: $2.67-$5.55
Congressional Interest in Prime Medicine, Inc. (PRME)
No congressional trades have been disclosed for Prime Medicine, Inc. (PRME) yet. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
0
Unique Politicians
0
Buys
0
Sells
0
Who in Congress Is Trading PRME?
No congressional trades found for this stock.